Quick Answer
MIRA PHARMACEUTICALS, INC. reported Diluted EPS of $1.35 per share (loss) for fiscal year 2025.
MIRA PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.35 | -164.7% |
| 2024 | -$0.51 | +40.0% |
| 2023 | -$0.85 | -112.5% |
| 2022 | -$0.40 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.18 | -742.9% | -1211.1% |
| June 30, 2025 | -$0.09 | +18.2% | +18.2% |
| March 31, 2025 | -$0.11 | +26.7% | +21.4% |
| September 30, 2024 | -$0.14 | +46.2% | -27.3% |
| June 30, 2024 | -$0.11 | -10.0% | +26.7% |
| March 31, 2024 | -$0.15 | -50.0% | +42.3% |
| September 30, 2023 | -$0.26 | -85.7% | -160.0% |
| June 30, 2023 | -$0.10 | +47.4% | +0.0% |
- MIRA PHARMACEUTICALS, INC. showed a decrease of -164.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, MIRA PHARMACEUTICALS, INC.’s diluted eps has declined by 237.5% (from $0.40 per share (loss) to $1.35 per share (loss)).
- The most recent figure is from MIRA PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: